Ridgeback received FDA priority review for ansuvimab to treat Ebola and will donate free drug for those in need in Africa during this ongoing Ebola outbreak. businesswire.com/news/home/2…
9
Happy to join forces to vanquish SARS-CoV-2 with our great partner Merck $MRK
businesswire.com/news/home/2…
Thanks to the great team at Ridgeback Bio for getting this promising medicine to patients in record time. businesswire.com/news/home/2…
MHRA clearance Thursday April 9. 80 people screened for Phase 1 on Good Friday. 1st person to receive EIDD-2801 this morning in the UK. Amazing teamwork. Fastest trial start ever. Go Ridgeback Go. #CureCovid19 #Covid19 #Ridgebackbio
prnewswire.com/news-releases…
Thanks to Tim Sheahan, Mark Denison, Ralph Baric, George Painter, Wendy Painter for all the great research on EIDD-2801. Human trials to start in days. #COVID19 #CURECOVID
Here is our new paper on an oral #antiviral drug that works against #SARSCoV2 #COVID19. A herculean effort w/ Amy Sims @Ardinajp @mariagoneviral @DenisonLab @KDinnon @aschaefe29 @SarahRLeist @Baric_Lab @DenisonLab @knowerofrandom stm.sciencemag.org/content/e…
Ridgeback to start human testing on EIDD-2801 within days. Oral investigational drug. Animal data in MERS and SARS shows early treatment prevents severe illness. We hope to prove the same in people with COVID-19. #COVID19 #CURECOVID19
Ridgeback announced today FDA cleared EIDD-2801 IND last Friday. Thank you FDA Comm. Hahn and Anti-Viral Division. So fast. So helpful. #COVID19 #FDA #EIDD2801 #RidgebackBiotherapeutics
Questions
1)Is there a relationship between severity of COVID-19 in 30-50 year olds and the exposure to RCCVs from kids through household (parents) and professional (MDs and teachers) contact?
2)Would greater prior exposure the RCCVs result in a milder COVID-19 disease course?
7
8)Prevalence of anti-RCCV antibodies declines with age in older adults
9)Antibodies to the RCCVs, SARS-COV-1 and MERS isolated from human samples can have some cross reactivity to each other
6
6)Adults with children are more frequently infected with the 4 RCCVs relative to adults without children
7)Teachers and pediatricians are more likely to be infected with the 4 RCCVs
5
3)Children are less likely to have severe disease with SARS-COV2
4)Younger kids will have had less exposure to RCCVs vs older kids
5)Within childhood age groups the youngest are more likely to have severe disease
4
Data reported in the medical literature:
1)There are 4 routinely circulating coronaviruses (RCCVs) that cause mild disease
2)Children are more routinely infected vs adults with the 4 RCCVs in published studies of subjects in NYC and China
4
Flattening the Curve: The South Korean Approach to COVID-19 medium.com/@stevejang/flatte…
What do we need to stop COVID? An oral, safe, effective drug! EIDD-2801 is all that in animals. On to human testing soon. #CLEARTHEPATH #Coronavirus #COVID

